By measuring two AD-related biomarkers in the brain, we confirmed that ZnCl2 exposure could significantly elevate the relative contents of Aβ42 (Figure 8H) and p-Tau (Figure 8I). The gene discussed is MAPT; the disease is Alzheimer disease.